PRAXIS Resource Repository Search our extensive library of COPD care and readmissions reduction resources, including best practices, research articles, educational materials and toolkits.
Return to all articles Return to previous page Hospital readmissions following initiation of nebulized arformoterol tartrate or nebulized short-acting beta-agonists among inpatients treated for COPD Resource Type: Research Papers 2 Comments This matched case-control study of nationally representative administrative data examined the relationship between treatment using arformoterol or nebulized SABA and 30-day all-cause readmissions. Readmissions were significantly lower in the group treated with arformoterol than those using nebulized SABA, both before and after controlling for initial admission variables. View Resource Citation: Bollu V, Ernst FR, Karafilidis J, Rajagopalan K, Robinson SB, Braman SS. Hospital readmissions following initiation of nebulized arformoterol tartrate or nebulized short-acting beta-agonists among inpatients treated for COPD. Int J Chron Obstruct Pulmon Dis. December 2013; (8): 631—639. DOI https://dx.doi.org/10.2147/COPD.S52557. Accessed March 18, 2020. exacerbations readmission treatment 2 Comments Newest First Oldest First Popular First Unpopular First You need to login to comment. KevinSMt In my area, I feel arformoterol, a nebulized long-acting beta agonist, is under prescribed in comparison to SABA nebulizer medicines. Education for both healthcare professionals and patients is needed to bring greater awareness to LABA benefits in helping patients with COPD. Reply
Return to all articles Return to previous page Hospital readmissions following initiation of nebulized arformoterol tartrate or nebulized short-acting beta-agonists among inpatients treated for COPD Resource Type: Research Papers 2 Comments This matched case-control study of nationally representative administrative data examined the relationship between treatment using arformoterol or nebulized SABA and 30-day all-cause readmissions. Readmissions were significantly lower in the group treated with arformoterol than those using nebulized SABA, both before and after controlling for initial admission variables. View Resource Citation: Bollu V, Ernst FR, Karafilidis J, Rajagopalan K, Robinson SB, Braman SS. Hospital readmissions following initiation of nebulized arformoterol tartrate or nebulized short-acting beta-agonists among inpatients treated for COPD. Int J Chron Obstruct Pulmon Dis. December 2013; (8): 631—639. DOI https://dx.doi.org/10.2147/COPD.S52557. Accessed March 18, 2020. exacerbations readmission treatment 2 Comments Newest First Oldest First Popular First Unpopular First You need to login to comment. KevinSMt In my area, I feel arformoterol, a nebulized long-acting beta agonist, is under prescribed in comparison to SABA nebulizer medicines. Education for both healthcare professionals and patients is needed to bring greater awareness to LABA benefits in helping patients with COPD. Reply
Join Us on COPD360social Join the Conversation Become a Member > Already a Member? Sign In to Participate >
Type of Resource View All Articles Articles (34) Case Studies (10) Educational Materials (9) Opinion/Editorials (10) Policy Statements (3) Presentations (5) Research Papers (80) Statistics (9) Toolkits (23) Webinars (8) White Papers/Reports (12)
Tags View All Articles 96readmission78hospitalization61treatment54patient education54promising practices54care coordination49evaluation & quality improvement45patient experience43exacerbations42co-morbidities42post-acute care37caregiver & community33telehealth28behavioral health27pulmonary rehabilitation27risk stratification25public policy22ambulatory care21diagnosis17prevention16HRRP13socioeconomic issues13exercise12oxygen12Palliative care5nutrition4hospice4Alpha-13readmissions2quality improvement1caregiver1COPD1care transitions1treatment guidelines1GOLD1improving care1research & quality improvement1hospitalizations